- Molecular NameMecamylamine
- Synonym2-Methylamino-2,3,3-trimethylnorbornane; 2-Methylaminoisocamphane; 3-Methylaminoisocamphane; 3-Methylaminoisocamphane hydrochloride; Mecamilamina; Mecamylamine Hydrochloride
- Weight167.296
- Drugbank_IDDB00657
- ACS_NO60-40-2
- Show 3D model
- LogP (experiment)2.477
- LogP (predicted, AB/LogP v2.0)2.57
- pka11.3
- LogD (pH=7, predicted)-0.5
- Solubility (experiment)Slightly soluble
- LogS (predicted, ACD/Labs)(ph=7)0.78
- LogSw (predicted, AB/LogsW2.0)1.38
- Sw (mg/ml) (predicted, ACD/Labs)2.31
- No.of HBond Donors1
- No.of HBond Acceptors1
- No.of Rotatable Bonds1
- TPSA12.03
- StatusFDA approved
- AdministrationN/A
- PharmacologyA voltage dependent non-competitive antagonist at nicotinic receptors.
- Absorption_valueN/A
- Absorption (description)Mecamylamine is almost completely absorbed after oral administration; high concentrations are found in the liver and kidney.
- Caco_2N/A
- BioavailabilityN/A
- Protein binding40.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmN/A
- Half lifeN/A
- ExcretionMore than 50% of a dose is excreted in 24 h as unchanged drug in acid urine; the excretion is reduced if the urine is alkaline.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityLabel side effects are listed below: Ileus, constipation, vomiting, nausea, anorexia, glossitis, dryness of mouth; orthostatic dizziness and syncope, postural hypotension; convulsions, choreiform movements, mental aberrations, tremor, paresthesias; intestitial pulmonary edema, fibrosis; urinary retention, impotence, decreased libido, weakness, fatigue, sedation.
- LD50 (rat)N/A
- LD50 (mouse)N/A